A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

ISIS Pharmaceuticals

About ISIS

Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-based technologies, such as antisense. Very little was known about antisense when the company was first established, but its founders envisioned an opportunity to revolutionize the pharmaceutical industry with a more efficient and targeted means of drug discovery.

Vitravene (fomivirsen) is the first antisense drug to achieve marketing clearance. Vitravene treats a condition called cytomegalovirus (CMV) retinitis in people with AIDS. Isis developed the drug and licensed the worldwide commercial rights to Novartis Ophthalmics (formerly CibaVision.)



Pipeline for ISIS


Alicaforsen (ISIS 2302) --patients with ulcerative colitis.

ISIS 113715 --Diabetes

ISIS 107248 -- Multiple Sclerosis

ISIS 301012 Cardiovascular

LY2181308 -- Cancer

ATL-1101 -- Psoriasis



More on ISIS

Home Page

Key Statistics for ISIS

Basic Chart for ISIS

Analyst Opinion

Analysts Estimates


Biotech100 Index
What are the Requirements to be listed in the Biotech100 Index?
See the Biotech100 List

Sponsored Links

Clinical Trials
What is a Clinical Trial?
Phase I ,-- Phase II, -- PhaseIII
What is Randomized Control?
 What is a Double Blind Experiment?
What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
Small Cap Stocks
Stocks and Bonds
Biotech100 Index

Careers and Employment
Biotechnology and Pharmaceutical
What are the Fastest Growing Careers?




Copyright 2005 BIOTECH100.COM. All rights reserved.